FOXP3 gene expression in multiple sclerosis patients pre- and post mesenchymal stem cell therapy

Area of Science:

• Neuroscience
• Immunology
• Regenerative Medicine

Background:

• Multiple Sclerosis (MS) is a CNS disorder causing neuroinflammation, axonal loss, and neurodegeneration, primarily affecting young adults.
• T lymphocytes drive the inflammatory cascade in MS pathogenesis.
• Current MS treatments lack a cure, highlighting the need for neuroprotective strategies.

Purpose of the Study:

• To evaluate the potential of bone marrow-derived mesenchymal stem cells (MSCs) as a neuroprotective therapy for MS.
• To assess the effect of MSC therapy on the expression of FoxP3, a marker for T regulatory cells, in MS patients.

Main Methods:

• A pilot study involving MS patients receiving intrathecal MSC therapy.
• Quantitative reverse transcription polymerase chain reaction (q RT-PCR) was used to measure FoxP3 expression in peripheral blood mononuclear cells before and after treatment.

Main Results:

• FoxP3 expression significantly increased in most patients 6 months post-MSC treatment compared to baseline levels.
• Enhanced FoxP3 expression was associated with clinical stability in the treated MS patients.

Conclusions:

• Bone marrow-derived MSC therapy shows potential for treating MS by enhancing T regulatory cell markers.
• MSC therapy may offer immune regulation and contribute to neurological repair in MS.
• Further research is warranted to confirm the efficacy and mechanisms of MSC therapy for MS.